_id
6915ec26bc934aba376b1d41
Ticker
RAPP
Name
Rapport Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
1325 Boylston Street, Boston, MA, United States, 02215
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.rapportrx.com
Description
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Last Close
28.09
Volume
245249
Current Price
27.1
Change
-0.59
Last Updated
2026-01-06T09:59:33.292Z
Image
data:image/webp;base64,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
Ipo Date
2024-06-07T00:00:00.000Z
Market Cap
1339754624
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.5916666666666667
Sentiment Sources
3
Rating
4.8
Target Price
52.25
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
29986000
Operating Income
-29986000
Interest Expense
-
Pretax Income
-26925000
Net Income
-26925000
Eps
-0.07098383730319946
Dividends Per Share
-
Shares Outstanding
47661138
Income Tax Expense
-
EBITDA
-26669000
Operating Margin
-
Total Other Income Expense Net
3061000
Cash
251359000
Short Term Investments
261667000
Receivables
-
Inventories
-
Total Current Assets
520659000
Property Plant Equipment
13596000
Total Assets
535323000
Payables
3235000
Short Term Debt
2482000
Long Term Debt
-
Total Liabilities
23706000
Equity
511617000
Bs_currency_symbol
USD
Depreciation
256000
Change In Working Capital
3698000
Cash From Operations
-17465000
Capital Expenditures
134000
Cash From Investing
-56776000
Cash From Financing
270533000
Net Change In Cash
196292000
Cf_currency_symbol
USD
PE
-
PB
20.091879413702046
ROE
-5.262725828109699
ROA
-5.029673673651234
FCF
-17599000
Fcf Percent
-
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
29986000
Quarters > 0 > income Statement > operating Income
-29986000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-26925000
Quarters > 0 > income Statement > net Income
-26925000
Quarters > 0 > income Statement > eps
-0.07098383730319946
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
379311700
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-26669000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
3061000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
251359000
Quarters > 0 > balance Sheet > short Term Investments
261667000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
520659000
Quarters > 0 > balance Sheet > property Plant Equipment
13596000
Quarters > 0 > balance Sheet > total Assets
535323000
Quarters > 0 > balance Sheet > payables
3235000
Quarters > 0 > balance Sheet > short Term Debt
2482000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
23706000
Quarters > 0 > balance Sheet > equity
511617000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-26925000
Quarters > 0 > cash Flow > depreciation
256000
Quarters > 0 > cash Flow > change In Working Capital
3698000
Quarters > 0 > cash Flow > cash From Operations
-17465000
Quarters > 0 > cash Flow > capital Expenditures
134000
Quarters > 0 > cash Flow > cash From Investing
-56776000
Quarters > 0 > cash Flow > cash From Financing
270533000
Quarters > 0 > cash Flow > net Change In Cash
196292000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.07098383730319946
Quarters > 0 > ratios > PB
20.091879413702046
Quarters > 0 > ratios > ROE
-5.262725828109699
Quarters > 0 > ratios > ROA
-5.029673673651234
Quarters > 0 > ratios > FCF
-17599000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
252000
Quarters > 1 > income Statement > gross Profit
-252000
Quarters > 1 > income Statement > operating Expenses
29496000
Quarters > 1 > income Statement > operating Income
-29496000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-26732000
Quarters > 1 > income Statement > net Income
-26732000
Quarters > 1 > income Statement > eps
-0.07541903027073067
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
354446350
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-29244000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2764000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
55067000
Quarters > 1 > balance Sheet > short Term Investments
205380000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
270242000
Quarters > 1 > balance Sheet > property Plant Equipment
14219000
Quarters > 1 > balance Sheet > total Assets
285495000
Quarters > 1 > balance Sheet > payables
3176000
Quarters > 1 > balance Sheet > short Term Debt
1759000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
21983000
Quarters > 1 > balance Sheet > equity
263512000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-26732000
Quarters > 1 > cash Flow > depreciation
252000
Quarters > 1 > cash Flow > change In Working Capital
-3370000
Quarters > 1 > cash Flow > cash From Operations
-25070000
Quarters > 1 > cash Flow > capital Expenditures
22000
Quarters > 1 > cash Flow > cash From Investing
22596000
Quarters > 1 > cash Flow > cash From Financing
-63000
Quarters > 1 > cash Flow > net Change In Cash
-2537000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.07541903027073067
Quarters > 1 > ratios > PB
36.45183553310665
Quarters > 1 > ratios > ROE
-10.144509547952275
Quarters > 1 > ratios > ROA
-9.36338639906128
Quarters > 1 > ratios > FCF
-25092000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
244000
Quarters > 2 > income Statement > gross Profit
-244000
Quarters > 2 > income Statement > operating Expenses
27108000
Quarters > 2 > income Statement > operating Income
-27108000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-24063000
Quarters > 2 > income Statement > net Income
-24063000
Quarters > 2 > income Statement > eps
-0.12475559558112911
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
192881128
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-26864000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
3045000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
57604000
Quarters > 2 > balance Sheet > short Term Investments
227778000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
290968000
Quarters > 2 > balance Sheet > property Plant Equipment
10874000
Quarters > 2 > balance Sheet > total Assets
302053000
Quarters > 2 > balance Sheet > payables
2139000
Quarters > 2 > balance Sheet > short Term Debt
1008000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
16217000
Quarters > 2 > balance Sheet > equity
285836000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-24063000
Quarters > 2 > cash Flow > depreciation
244000
Quarters > 2 > cash Flow > change In Working Capital
-433000
Quarters > 2 > cash Flow > cash From Operations
-20237000
Quarters > 2 > cash Flow > capital Expenditures
291000
Quarters > 2 > cash Flow > cash From Investing
21031000
Quarters > 2 > cash Flow > cash From Financing
5000
Quarters > 2 > cash Flow > net Change In Cash
799000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.12475559558112911
Quarters > 2 > ratios > PB
18.286984735302763
Quarters > 2 > ratios > ROE
-8.418463734449125
Quarters > 2 > ratios > ROA
-7.966482703366627
Quarters > 2 > ratios > FCF
-20528000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
720000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
360000
Quarters > 3 > income Statement > operating Expenses
23521000
Quarters > 3 > income Statement > operating Income
-23521000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-19980000
Quarters > 3 > income Statement > net Income
-19980000
Quarters > 3 > income Statement > eps
-0.10358711713880064
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
192881128
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-23261000
Quarters > 3 > income Statement > operating Margin
-3266.8055555555557
Quarters > 3 > income Statement > total Other Income Expense Net
3541000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
56805000
Quarters > 3 > balance Sheet > short Term Investments
248475000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
309802000
Quarters > 3 > balance Sheet > property Plant Equipment
4971000
Quarters > 3 > balance Sheet > total Assets
314933000
Quarters > 3 > balance Sheet > payables
1954000
Quarters > 3 > balance Sheet > short Term Debt
737000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
9506000
Quarters > 3 > balance Sheet > equity
305427000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-19980000
Quarters > 3 > cash Flow > depreciation
260000
Quarters > 3 > cash Flow > change In Working Capital
1341000
Quarters > 3 > cash Flow > cash From Operations
-14446000
Quarters > 3 > cash Flow > capital Expenditures
226000
Quarters > 3 > cash Flow > cash From Investing
31930000
Quarters > 3 > cash Flow > cash From Financing
7000
Quarters > 3 > cash Flow > net Change In Cash
17491000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.10358711713880064
Quarters > 3 > ratios > PB
17.114002916572538
Quarters > 3 > ratios > ROE
-6.541661346246403
Quarters > 3 > ratios > ROA
-6.344206545519206
Quarters > 3 > ratios > FCF
-14672000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-20.377777777777776
Quarters > 3 > health Score
27
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
839000
Annuals > 0 > income Statement > gross Profit
-839000
Annuals > 0 > income Statement > operating Expenses
82216000
Annuals > 0 > income Statement > operating Income
-83055000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-78307000
Annuals > 0 > income Statement > net Income
-78307000
Annuals > 0 > income Statement > eps
-0.3775953502156248
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
207383380
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-77468000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
4748000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
56805000
Annuals > 0 > balance Sheet > short Term Investments
248475000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
309802000
Annuals > 0 > balance Sheet > property Plant Equipment
4971000
Annuals > 0 > balance Sheet > total Assets
314933000
Annuals > 0 > balance Sheet > payables
1954000
Annuals > 0 > balance Sheet > short Term Debt
737000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
9506000
Annuals > 0 > balance Sheet > equity
305427000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-78307000
Annuals > 0 > cash Flow > depreciation
839000
Annuals > 0 > cash Flow > change In Working Capital
-2416000
Annuals > 0 > cash Flow > cash From Operations
-64828000
Annuals > 0 > cash Flow > capital Expenditures
2405000
Annuals > 0 > cash Flow > cash From Investing
-170141000
Annuals > 0 > cash Flow > cash From Financing
221625000
Annuals > 0 > cash Flow > net Change In Cash
-13344000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-0.3775953502156248
Annuals > 0 > ratios > PB
18.685940069476505
Annuals > 0 > ratios > ROE
-25.638532284310163
Annuals > 0 > ratios > ROA
-24.864653751750375
Annuals > 0 > ratios > FCF
-67233000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
26
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
112000
Annuals > 1 > income Statement > gross Profit
-112000
Annuals > 1 > income Statement > operating Expenses
36067000
Annuals > 1 > income Statement > operating Income
-36179000
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-34776000
Annuals > 1 > income Statement > net Income
-34786000
Annuals > 1 > income Statement > eps
-0.19241306107115663
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
180788143
Annuals > 1 > income Statement > income Tax Expense
10000
Annuals > 1 > income Statement > EBITDA
-34664000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
1403000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
70169000
Annuals > 1 > balance Sheet > short Term Investments
77309000
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
150872000
Annuals > 1 > balance Sheet > property Plant Equipment
4000000
Annuals > 1 > balance Sheet > total Assets
155423000
Annuals > 1 > balance Sheet > payables
2502000
Annuals > 1 > balance Sheet > short Term Debt
670000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
181057000
Annuals > 1 > balance Sheet > equity
-25634000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-34786000
Annuals > 1 > cash Flow > depreciation
112000
Annuals > 1 > cash Flow > change In Working Capital
2652000
Annuals > 1 > cash Flow > cash From Operations
-27181000
Annuals > 1 > cash Flow > capital Expenditures
1636000
Annuals > 1 > cash Flow > cash From Investing
-78860000
Annuals > 1 > cash Flow > cash From Financing
145136000
Annuals > 1 > cash Flow > net Change In Cash
39095000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.19241306107115663
Annuals > 1 > ratios > PB
-194.08947863618633
Annuals > 1 > ratios > ROE
135.7025825076071
Annuals > 1 > ratios > ROA
-22.3815008074738
Annuals > 1 > ratios > FCF
-28817000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
-
Annuals > 2 > income Statement > cost Of Revenue
15000
Annuals > 2 > income Statement > gross Profit
-15000
Annuals > 2 > income Statement > operating Expenses
10352000
Annuals > 2 > income Statement > operating Income
-10367000
Annuals > 2 > income Statement > interest Expense
285000
Annuals > 2 > income Statement > pretax Income
-10652000
Annuals > 2 > income Statement > net Income
-10652000
Annuals > 2 > income Statement > eps
-0.05295010579930218
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
201170514
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-10352000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-285000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
31159000
Annuals > 2 > balance Sheet > short Term Investments
0
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
31268000
Annuals > 2 > balance Sheet > property Plant Equipment
335000
Annuals > 2 > balance Sheet > total Assets
31603000
Annuals > 2 > balance Sheet > payables
1450000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
12098000
Annuals > 2 > balance Sheet > equity
19505000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-10652000
Annuals > 2 > cash Flow > depreciation
16364
Annuals > 2 > cash Flow > change In Working Capital
1488000
Annuals > 2 > cash Flow > cash From Operations
-3242000
Annuals > 2 > cash Flow > capital Expenditures
284000
Annuals > 2 > cash Flow > cash From Investing
-5284000
Annuals > 2 > cash Flow > cash From Financing
39685000
Annuals > 2 > cash Flow > net Change In Cash
31159000
Annuals > 2 > cash Flow > currency_symbol
-
Annuals > 2 > ratios > PE
-0.05295010579930218
Annuals > 2 > ratios > PB
283.8355573073571
Annuals > 2 > ratios > ROE
-54.61163804152781
Annuals > 2 > ratios > ROA
-33.70566085498212
Annuals > 2 > ratios > FCF
-3526000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
31
Valuation > metrics > PE
-0.07098383730319946
Valuation > metrics > PB
20.091879413702046
Valuation > final Score
20
Valuation > verdict
569.7% Overvalued
Profitability > metrics > ROE
-5.262725828109699
Profitability > metrics > ROA
-5.171330947894879
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.04633544233283882
Risk > metrics > Interest Coverage
-117.1328125
Risk > final Score
-409
Risk > verdict
High
Liquidity > metrics > Current Ratio
91.07206576875984
Liquidity > metrics > Quick Ratio
91.07206576875984
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
13
Prev Risks > 1
21
Prev Risks > 2
31
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:27:51.612Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-06
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.71
Earnings History > 0 > eps Estimate
-0.732
Earnings History > 0 > eps Difference
0.022
Earnings History > 0 > surprise Percent
3.0055
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-07
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.75
Earnings History > 1 > eps Estimate
-0.77
Earnings History > 1 > eps Difference
0.02
Earnings History > 1 > surprise Percent
2.5974
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-08
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.68
Earnings History > 2 > eps Estimate
-0.745
Earnings History > 2 > eps Difference
0.065
Earnings History > 2 > surprise Percent
8.7248
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-11
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.57
Earnings History > 3 > eps Estimate
-0.7
Earnings History > 3 > eps Difference
0.13
Earnings History > 3 > surprise Percent
18.5714
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-07
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.5
Earnings History > 4 > eps Estimate
-0.52
Earnings History > 4 > eps Difference
0.02
Earnings History > 4 > surprise Percent
3.8462
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-08
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-1.7
Earnings History > 5 > eps Estimate
-0.68
Earnings History > 5 > eps Difference
-1.02
Earnings History > 5 > surprise Percent
-150
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-29
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-1.12
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-1.12
Earnings History > 6 > surprise Percent
-
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AShort Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% - Defense World
1/21/2026
Short Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% Defense World
Read more →Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$52.25
Analyst Picks
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Rapport Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.71
EPS Estimate
-0.732
EPS Difference
0.022
Surprise Percent
3.0055%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.